Transcript Highlights:

• Um, but one of the things that popped up for me was, there's kind of a turf war between the FDA and the
• FDA has the jurisdiction to make sure that the lab portion of it is done safely, and then the USDA has
• and the USDA about who had the FDA and the USDA about who had regulatory<00:07:29.759> authority<
• <00:07:34.960> um<00:07:35.280> FDA<00:07:35.840> has<00:07:36.400> the
• c><00:07:37.120> jurisdiction of them do. um FDA has the jurisdiction of them do. um FDA has the

Keywords: Meeting Start: 00:00 Attendance Roll Call: 00:25 HB 309 Discussion: 00:49 HB 308 Roll Call Vote: 11:34, 958, all

Summary: The House Agriculture Committee met with a quorum and first introduced legislative interns before taking up House Bill 309, sponsored by Representative Ryan Dodson and co-sponsored by Representative Scott Sharp. The bill would ban lab-grown meat in Kentucky, with the sponsor arguing it was needed to protect Kentucky’s cattle, livestock, and broader agricultural industries, and citing uncertainty about the long-term effects of cultured meat. Supporters also said the state should defend traditional animal agriculture and that the bill had backing from livestock interests and the Kentucky Commissioner of Agriculture. Members raised several concerns, including whether labeling rather than a ban would be a better approach, whether the bill could conflict with the dormant commerce clause, and whether it might hinder emerging research or business opportunities in Kentucky. Some members compared the proposal to existing regulation of other products, while others said they supported the intent but were uneasy about a total ban. The sponsor responded that Kentucky should act to protect its farmers and that the issue could be revisited later if new research emerged. After discussion, the committee took a roll call vote. The bill received enough support to advance, with the chair announcing that House Bill 309 passed with favorable expression and should also pass on the House floor. Several members explained yes, no, or pass votes, reflecting a mix of support for Kentucky agriculture and concern about overbroad regulation and possible legal issues. The meeting then adjourned.

Transcript Highlights:

• That would not be FDA regulated.
• schedule 3 as it is because the uh FDA schedule 3 as it is because the uh FDA doesn't<01:57:34.480
• The FDA has been asking prescription.
• those kinds of products FDA approved those kinds of products FDA approved >> so<01:58:31.119
• <01:58:35.119> approved FDA approved FDA approved cannabonoid<01:58:37.360> based<01:58

Bills: HB1974, HB1853, HB1973, HB1574, HB2619, HB1966, HB1643, HB1671, HB2558, HB1854, HB2173, HB1575, HB2229, HB1535, HB1978, HB2508, HB1549, HB2187, HB1550, HB1977, HB2314, HB1871, HB2319, HB1591, HB1858, HB1898, HB2372, HB1765, HB2012, HB1706, HB1962, HB1963, HB1975, HB2009, HB2083, HB2224, HB1877, HB1959, HB1626, HB1665, HB2488, HB2456, HB2548, HB2207, HB1832, HB2079, HB1985, HB1618, HB2486, HB2242, HB2045, HB1703, HB2236, HB2480, HB1976, HB2287, HB2288, HB1777, HB276, HB1660, HB1676, HB1605, HB1751, HB1967, HB2383, HB2340, HB1946, HB2268, HB1950, HB2156, HB2118, HB1859, HB1863, HB1996, HB2114, HB2423, HB2429, HB2475, HB2534, HB2545, HB1813, HB1941, HB2474, HB2583, HB1576, HB1886, HB1939, HB2540, HB2590, HB2000, HB2163, HB2386, HB1691, HB1680, HB2516, HB1993, HB2442, HB1510, HB1958, HB1692

Keywords: HB1974, hearing loss, audiology, audiologist, hearing screening, hearing aids, cochlear implants, tele-audiology, communication access, assistive technology, speech-language pathology, deafness, hard of hearing, public health, kupuna, keiki, dementia, cognitive decline, fall prevention, State Health Planning and Development Agency

Transcript Highlights:

• WILL THE INSURANCE COMPANIES RESPOND TO THERAPIES AUTHORIZED UNDER THIS BILL BUT NOT APPROVED BY THE FDA
• RESPOND TO THERAPIES AUTHORIZED UNDER THIS BILL BUT NOT APPROVED BY THE FDA?
• GETTING AN UNREGULATED TREATMENT VERSUS A REGULATED THERAPY, THERAPY THAT HAS BEEN APPROVED BY THE FDA
• NOT ONLY IS IT NOT FDA APPROVED BUT ALSO INDICATES THE CONTRAINDICATIONS.
• LOTS OF DIFFERENT THINGS WHERE WE HAVE OFF LABEL TREATMENT OPTIONS FOR PATIENTS ON THINGS THAT ARE FDA

Keywords: 999, senate, all

Transcript Highlights:

• , there are currently five consumer products that have completed pre-market consultations under the FDA
• He added that the product is FDA approved, maintained as safe by the U.S. federal government, and that
• He stated that it is FDA approved and maintained as safe by the U.S. federal government.
• The chair said he was not sure whether the witness had worked directly with the FDA or USDA, but noted
• The FDA has approved it.

Bills: HB2155, HB2156, HB2162, HB2762, HB2791

Keywords: Arizona Beef Council, agriculture, market development, beef products, terminating council, livestock, compensation, funding, ranching, game and fish commission, wildlife, appointment, commission membership, Arizona Revised Statutes, food labeling, cultivated cells, cell-cultured products, consumer information, food safety, cell-cultured protein

Summary: The House Committee on Land, Agriculture, and Rural Affairs met for its first session, with members and staff introducing themselves before taking up committee-of-reference business and several bills. The committee first heard a presentation from the Arizona Beef Council, which described its checkoff-funded promotion, education, and research work for Arizona beef producers, including classroom materials, nutrition outreach, and ranch tours. After questions about how the program is funded and whether the state would lose its Arizona-retained share if the council were not continued, the committee voted to recommend continuing the council for eight years, until July 1, 2034. The committee then considered HB 2155, which also continued the Arizona Beef Council for eight years, and advanced it on a 7-1 vote. HB 2156, which appropriates money to the livestock compensation fund for wolf depredation losses, was amended to set the appropriation at $250,000 from the general fund in fiscal year 2027 and then passed 5-2, with supporters emphasizing rancher compensation and opponents questioning use of general funds and noting unused prior funding. HB 2162, which would require at least one Arizona Game and Fish Commission member to be a cattleman or rancher, drew testimony for and against but was ultimately held by the chair after discussion about representation, existing appointment structures, and rural interests. The committee also advanced two cell-cultured protein bills. HB 2762 would require a disclaimer on packaging for food derived from cultivated cells; supporters argued for consumer transparency and opponents said federal labeling rules already apply and state-specific requirements could create confusion. It passed 5-3. HB 2791 would prohibit the sale of cell-cultured protein for human consumption and make violations a felony; supporters raised safety, innovation, and agricultural concerns, while opponents argued it would criminalize federally approved products and restrict consumer choice. That bill also passed 5-3. The committee adjourned after completing its agenda.

Transcript Highlights:

• FDA investigational new drug trials for the ibogaine treatment of opioid. use disorder, co-occurring
• All research must be FDA IND approved.
• FDA. So we don't think there's any roadblock. The FDA already is.
• Again, we have to go through the FDA IND process and so there's real structure and rigor.
• On December 14, 1995, the FDA approved Purdue Pharmaceuticals OxyContin for, quote, the management of

Bills: SB128, SB640, SB672, SB904, SB1141, SB1263, SB1525, SB1528, SB2041, SB2306, SB2308, SB2357, SB2446, SB2695, SB2857, SB2891, SB2583

Keywords: hospital reporting, child abuse, neglect, administrative penalty, medical ethics, child protection, SB 640, Texas Family Code, Department of Family and Protective Services, DFPS, child welfare, foster care, managing conservatorship, suicide attempt, youth suicide, mental health, child protective services, state custody, annual report, reporting requirements

Transcript Highlights:

• 1800 bad drug and report it to the FDA 1800 bad drug and report it to the FDA because<00:04:41.000
• So thank you very much. review the FDA guideline with parents review the FDA guideline with parents and
• on the FDA on the FDA website<02:01:14.639> so<02:01:15.119> thank<02:01:15.280>
• Representative Cordelli said he did not believe so, because the FDA guidelines are available on the FDA
• <02:06:53.119> medication couple um one is so the FDA medication couple um one is so the FDA

Keywords: 1191, senate, all

Transcript Highlights:

• Fali and people at the CDC and FDA have refuted this.
• , not all people within the CDC and FDA, but some people within the CDC and FDA, have been suppressing
• the CDC and FDA have refuted this. the CDC and FDA have refuted this.
• , not all people within the CDC and FDA, not all people within the CDC and the<00:37:49.520> FDA,<
• , but some people within the CDC the FDA, but some people within the CDC and<00:37:52.000> FDA

Keywords: 928, house, all

Summary: The committee met to review its mission and to discuss recent work on a letter sent to the governor and legislative leaders regarding COVID vaccine safety and related scientific references. Members said the letter, which included 31 cited sources, had been delivered to the governor’s office, the Speaker’s office, and the Senate President’s office, and a press release had been issued. Several members defended the letter’s sourcing and urged the public to read the materials and evaluate the evidence themselves, while also acknowledging questions about the trustworthiness of some cited articles. A major portion of the meeting focused on a research assistant’s effort to use AI tools to help reconstruct and verify the committee’s 2024 COVID report with citations. She reported mixed results from Copilot and Gemini, noting that the tools often produced broad or incomplete outputs and that she would need to break the report into smaller sections and ask for more specific source types. Members advised using more precise prompts and emphasized that any AI output would still need human verification. The committee said it hoped to produce a revised, fully footnoted 2024 report by early September. The chair then outlined the committee’s fall agenda, saying it would examine long COVID treatment, the patient bill of rights as it relates to COVID vaccinations and death reporting, standards of care and professional judgment by New Hampshire health care providers, and oversight of federal COVID-related funding such as CARES Act education relief dollars. He also referenced a recent fraud case involving misuse of COVID funds and suggested the committee may ask the DOJ for information. The committee will not meet in July or August and plans to resume in September and October, with a final report targeted for the end of October. The chair also introduced a recent DNI/Tulsi Gabbard press release about U.S.-funded biolabs overseas, which members discussed as a possible transparency issue relevant to future pandemic policy.

Transcript Highlights:

• And the FDA is supposed to be coming out with something. It was due two weeks ago.
• You would still need FDA-approved drugs. There are no FDA-approved cannabis drugs.
• would still need FDA approved drugs. would still need FDA approved drugs.
• <00:35:28.640> cannabis There are no FDA approved cannabis There are no FDA approved cannabis
• <00:37:07.200> or that basically required um the FDA or that basically required um the FDA

Keywords: 912, senate, all

Summary: The committee first heard SB 888, which would bar operators of smart household security devices from sharing user data with law enforcement unless the user consents or police obtain a warrant. DCCA’s Office of Consumer Protection offered comments and Judiciary submitted written support. Several individuals also submitted written support. The committee recommended passage with amendments clarifying that the Office of Consumer Protection may enforce violations and adopting Judiciary’s recommended changes, while also deferring the effective date to July 1, 2050. The motion passed unanimously among members present, with one senator excused. The committee then took up SB 2777 on insurance disclosures. The bill would require authorized insurers to disclose claim-handling data to consumers, including claims open at the start of a period, closed with payment, closed without payment, and open at the end of the period. The committee described amendments to clarify the bill, remove a requirement for the DCCA insurance division to handle publication, and defer the effective date to July 1, 2050. The measure was passed with amendments and the recommendation was adopted, with one member voting no and another excused. In a joint Commerce and Consumer Protection/Judiciary hearing on SP2738 relating to tax haven abuse, the Department of Taxation offered comments and the Tax Foundation testified in opposition, arguing the state should rely on IRS audits and existing worldwide reporting rules rather than create a separate state approach. Other written testimony was noted in both support and opposition. The committees recommended passage with amendments adopting Taxation’s technical changes and deferring the effective date to July 1, 2050; the recommendation was adopted, with one senator noting reservations. The joint hearing then moved to health-related bills, including SB 2690 on primary care spending, SB 3103 on energy assistance, SB 3137 on Department of Health authority over food, drugs, and cosmetics, SB 3164 on child welfare service organizations, and SB 3206 on cannabinoids. SB 2690 drew strong support from physicians and advocates who said it would address primary care shortages, especially on neighbor islands, while HMSA and others warned a fixed spending percentage could raise costs and suggested a working group. SB 3164 drew support from child welfare providers and opposition from the Attorney General over indemnification language, and SB 3206 drew mixed testimony: state agencies raised federal-law and vagueness concerns, while hemp and cannabis advocates and some farmers supported the measure and urged broader legalization or amendments.

Transcript Highlights:

• change in the federal government in 2025, but states have to approve this so that our pharmacists can be FDA
• change in the federal government in 2025, but states have to approve this so that our pharmacists can be FDA
• change in the federal government in 2025, but states have to approve this so that our pharmacists can be FDA
• change in the federal government in 2025, but states have to approve this so that our pharmacists can be FDA
• "Our pharmacists can be FDA approved by this 8-hour training. It's voluntary, they can do this.

Keywords: 1183, house

Summary: House File 4493 would authorize pharmacists to initiate, prescribe, administer, and dispense certain drugs for opioid use disorder, especially buprenorphine/Suboxone. Representative Baker said the bill is intended to save lives by giving people immediate access to treatment at the moment they seek help, rather than making them wait for a doctor’s appointment or navigate more cumbersome methadone access. He emphasized that pharmacists are widely accessible, including in greater Minnesota, and that optional training would support safe prescribing. Representative Bierman spoke in strong support, calling the measure a life-or-death step forward for people with substance use disorder and noting that many people do not receive treatment when they need it. He said he initially had concerns but Baker listened to his suggested changes and worked with him and bill drafters, which helped address those concerns. Bierman also referenced the ongoing fentanyl crisis and encouraged members to learn more from displays honoring overdose victims. Baker closed by sharing personal remarks about losing his son to addiction and describing how limited treatment options were at that time. He said the new federal change allowing pharmacist training makes the bill timely and urged members to support it. After discussion, the House took a roll call vote and passed the bill 134-0, with the title agreed to.

Transcript Highlights:

• FDA, from what I understand. You're recognized. Thank you, Representative.
• According to the FDA, about 1.7 million Americans have used it.
• The FDA has not approved Kratom for any medical use, and there's no prescription for it.
• The FDA has deemed Kratom not appropriate for use as a dietary supplement and has deemed it unsafe as
• You see what the FDA website says, and there's a lot of negativity out there.

Transcript Highlights:

• These mini-boilers are heavily regulated by the FDA.
• You said you have to present a dossier to the FDA before they approve them.
• And then FDA requires every medical device manufacturer to submit a report within 10 days of any sort
• If I might just follow up on Senator Menendez's question to clarify, if the FDA were to cease to exist
• So, if that is no longer... in existence, they can no longer be cleared or regulated by the FDA.

Bills: SB264, SB542, SB924, SB1008, SB1029, SB1036, SB1057, SB1058, SB1185, SB1202, SB1358, SB1364, SB1376, SB1569, SB1664, SB1697, SJR50

Keywords: SB 264, Texas Workers' Compensation Act, group self-insurance, self-insured groups, workers' compensation, Texas Department of Insurance, commissioner of insurance, certificate of approval, guaranty fund, trust fund, wind down, dissolution, labor code, insurance regulation, employer coverage, risk pool, business and commerce, trade workforce economic development, property owners' association, water conservation

Transcript Highlights:

• Program Act, creates a highly controlled, science-driven pathway to test whether I can become safe FDA
• can become safe FDA approved medication for<00:19:45.200> opioid<00:19:45.840> use<00:
• It confines activity to FDA-regulated research and future FDA-approved medical use.
• It confines activity to FDA-regulated research and future FDA-approved medical use.
• It keeps us firmly within FDA crisis.

Keywords: MS House Floor - 21 January, 2026; 2:00 PM, 925, all

Summary: The House opened with prayer, the Pledge of Allegiance, a quorum call, and several guest introductions, including a pastor, a doctor of the day, medical students and physicians for MSMA White Coat Day, and visitors in the galleries. The chamber then moved to the calendar and took up House Bill 314, the Ibogaine Treatment Drug Development Grant Program Act. The sponsor described ibogaine as a potential treatment for opioid use disorder, PTSD, traumatic brain injury, depression, and related conditions, emphasizing that the bill would not legalize the drug but would authorize the State Department of Health to fund a consortium for FDA-regulated clinical trials with private matching funds, a university and hospital partner, and a requirement that at least 20% of commercialization revenue go to the state. Members asked about VA involvement, whether the trials would serve veterans or civilians, how the drug would be administered and monitored, why a statute was needed, and the source of the proposed state funding. The bill passed by a vote of 110 yeas and 1 nay. The House then considered House Bill 534, as a committee substitute, creating the Mississippi Health Exchange, a statewide health information exchange for real-time sharing of admission, discharge, transfer, and related patient information among hospitals, clinics, payers, and public health officials. The sponsor said the system would improve continuity of care, help with bed availability and mental health placements, and support public health analysis while protecting privacy through HIPAA compliance, an opt-out process, and limits on access to identified data. The bill would require hospitals, community mental health centers, and state hospitals to participate as a condition of licensure, designate a single nonprofit operator selected by the Department of Health, and create a fund for implementation and cybersecurity costs. Members questioned the bill about privacy protections, the opt-out process, whether data could be sold or shared improperly, costs to hospitals, whether hospitals and the hospital association supported the measure, and how the exchange would work in transfer scenarios. The sponsor said the bill would make unauthorized sharing illegal, that most hospitals already participate in some form of HIE, and that the exchange would not cost the state anything immediately because there was no appropriation attached. The discussion also noted possible help from rural transformation funding. The transcript ends during continued questioning of House Bill 534, before final passage or other action is shown.

Transcript Highlights:

• Please support this bill and support Texas shrimpers and the FDA. ...to stay in business and continue
• And we have no idea, because the FDA is testing less than 1% of this stuff, we have no idea what was
• What standards does the FDA have?
• Yeah, no, the FDA does have standards. What's banned is...
• The FDA catches people doing this every quarter, and they're only testing less than one percent.

Bills: HB2226, HB2269, HB2343, HB2760, HB3621, HB4079, HB4204, HB4518, HB4531, HB4555, HB4850, HB4876, HB4903, HB4996, HB5122

Keywords: construction trust funds, Property Code, Chapter 162, construction payments, mechanics lien, contractors, subcontractors, laborers, material suppliers, materialmen, real property improvement, assignment of payment rights, unpaid trust funds, trust fund beneficiaries, construction industry, payment protection, Texas construction law, property owners association, landscaping, grass maintenance

Transcript Highlights:

• The FDA, under the Biden administration, changed the rules for the chemical abortion drug.
• NIH and FDA to do that.
• My question is, if confirmed as Secretary of HHS, will you commit to working with the FDA Commission
• And now the FDA has acknowledged that and banned it.
• And Project Warp Speed had CDC, FDA, NIH, and BARDA very much in the mix.

Transcript Highlights:

• It confines the activity to FDA-regulated research and future FDA-approved medical use.
• There's FDA coordination and trial sites.
• There's FDA coordination and trial sites.
• It confines the activity to FDA-regulated research and future FDA-approved medical use.
• There's FDA coordination and trial sites.

Keywords: MS Senate Floor - 5 March, 2026; 10:00 AM, 925, all

Summary: The Senate convened with a quorum, opened with an invocation by Dr. Ryan Wade and the Pledge of Allegiance, and then handled routine business by dispensing with the reading of the journal and committee reports. Several guests were recognized, including Leadership Jackson County, Farm Bureau members, a doctor of the day, adult educators, and other visitors in the gallery. Senator Brumfield also announced support efforts for Senator Warren Barnett, asking members to contribute to him through Ms. Anita Jackson. The chamber then considered a series of House bills, most of them taken up with strike-all amendments and passed by use of the morning roll call. Measures included HB 1390 on personal services funding allocations, HB 1571 on ARPA funds and unexpended balances, HB 1655 on the State Aid Road Construction director’s personnel status, HB 1650 on dormant state accounts and pooled investments, HB 1651 on state agencies using other agencies’ facilities and charging 50% of fair market value, HB 1345 on administrative forfeiture of illegal cigarette and vaping products, HB 1386 on allowing sidewalks as an eligible use of municipal infrastructure funds, HB 671 on alcoholic beverage delivery responsibility ending when retailers transfer possession to delivery services, and HB 1385 on eliminating paper-original homestead exemption submissions. Members asked questions on several bills, especially about whether the fairgrounds language in HB 1651 would affect youth livestock shows and whether HB 1386 or other measures would change county revenue; sponsors generally said the bills were intended to address state-agency use, municipal reporting, or administrative efficiency rather than alter those programs. The Senate also advanced HB 898, creating a sales tax diversion study committee to review misallocated municipal sales tax revenues, assess impacts, examine technology and oversight, and recommend reforms by the 2027 session; Senator Hill questioned whether counties should be included, but the sponsor said that would be a separate policy decision. Later, the Senate reconsidered HB 1265, the Mississippi Debt Management Services Act extended repealer, adopted an amendment to remove the repealer instead of extending it, and then passed the bill. The body also took up SB 2632, the local governments disaster recovery emergency loan program, and voted not to concur and to invite conference. Finally, HB 1142 on bench warrant notices was called up; the sponsor explained a strike-all that would replace certified mail with personal service or electronic transmission and include a reverse repealer for further conference work.

Transcript Highlights:

• education and preparation for FDA education and preparation for FDA approval<00:50:14.839> when
• Without early action, FDA approval alone will not ensure success.
• Without early action, FDA approval alone will not ensure success.
• to get training in those prior to FDA to get training in those prior to FDA approval<01:07:02.440
• these therapies recognized by the FDA these therapies recognized by the FDA for<01:10:18.159>

Keywords: 910, house, all

Transcript Highlights:

• But to be clear, as is acknowledged by the labels, the FDA research, and further scientific research—I
• However, there is some confusion because of changing definitions of pregnancy and the FDA looking at
• It says an emergency contraceptive approved by the US FDA to prevent pregnancy by delaying ovulation.
• The handout that we just gave y'all actually has the FDA label that says this product works mainly to
• The new statement that the FDA put out did not specifically address this question, and so that's what

Bills: HB220, HB783, HB2240, HB3336, HB4202, HB4449, HB4904, HB3441, HB4284

Keywords: sexual assault, healthcare facilities, forensic examination, survivor support, emergency contraceptive, online impersonation, civil liability, social media, identity theft, defamation, counseling damages, injunctive relief, public health, safety regulations, community health, state standards, healthcare access, HB 3336, alcoholic beverage tax credit, spent grain

Transcript Highlights:

• So in April, we got the DOJ final order that placed FDA-approved cannabis products and medical cannabis
• It covers only two types of cannabis products: one, FDA-approved drugs containing Delta-9 THC from the
• The order also imposes regulatory requirements on FDA-approved cannabis products, not very surprising
• There are enforcement concerns regarding a lack of resources at FDA and the U.S.
• does not apply to cannabis products sold as foods, supplements, or unapproved drugs regulated by the FDA

Keywords: Cannabis Retail Market, Joint Commission to Oversee the Transition of the Commonwealth into a, 976, house, all

Summary: The Joint Commission on Cannabis and Hemp Policy met for its first meeting of 2026, elected Senator Lashrecse Aird as chair and Delegate Paul Krizek as vice chair, confirmed a quorum, adopted the virtual participation policy, and heard member introductions. Opening remarks emphasized the commission’s ongoing charge under HJR 497 to oversee Virginia’s transition toward a regulated retail cannabis market, with leaders noting that cannabis possession and home cultivation are already legal but retail sales remain unregulated and that the commission’s work continues despite the veto of the 2026 retail market bill. The commission then received a virtual briefing from NCSL on federal cannabis and hemp developments. Presenters explained the federal rescheduling of certain cannabis products to Schedule III, stressing that it applies only to FDA-approved cannabis drugs and state medical cannabis products, does not legalize adult-use sales, and leaves unresolved issues such as banking and broader tax compliance. They also reviewed the 2026 federal hemp changes narrowing the hemp definition, effective November 12, 2026, and warned of enforcement, interstate commerce, and market-disruption concerns for hemp-derived products. Members asked questions about whether rescheduling could lead to decriminalization and about tax and compliance implications for states. Commission staff then reviewed Virginia’s cannabis-related legislation from the 2026 session. They summarized bills that became law, including a process for modifying certain pre-2021 marijuana-related sentences, a bill allowing the Department of Health to address cannabis oil use in hospitals and convene a work group on medical-care-facility access, and a medical cannabis labeling/delivery measure. They also described SB 543, which strengthened hemp and illicit cannabis enforcement by requiring license decals, creating penalties for unlicensed sales and false decals, authorizing cease-and-desist actions and seizures, establishing a public tip line, directing law-enforcement training, and creating a consumer-protection civil action for certain high-THC products. No public comments were offered, and the meeting adjourned without further action.

Transcript Highlights:

• current mental health infrastructure or trained workforce to support equitable access to care after FDA
• : begin making investments into workforce development and training through the funding of FDA clinical
• <01:18:40.920> one<01:18:41.040> of<01:18:41.199> the designation by the FDA
• one of the designation by the FDA one of the reasons<01:18:42.159> MDMA<01:18:42.880> got<
• of which have been designated by the FDA of which have been designated by the FDA is<01:19:54.880

Keywords: 910, house, all

Summary: The Committee on Health heard testimony on several bills. On SB 1441, which would repeal the transfer of the Oahu Regional Health Care System from HHSC to the Department of Health, the Department of Health said it strongly supports the measure and requested clarifying amendments. HHSC/Oahu Region also supported the bill and said it had no objection to the department’s amendments. In response to questions, witnesses said the agencies have been working on an MOU to support transfers of long-term care patients to Leahi, with the current goal being about 10 to 15 patients, but transfers would occur only as space and staffing allow; one patient was reportedly being admitted at the time, and the process was described as slow and case-by-case. The committee then heard SB 1443 on payment rates for state hospital patients and related Department of Health services. The hospital administrator said the bill would allow rates above Medicaid for community or foster-home placements if patients cannot be placed at Leahi or elsewhere, and would set Medicaid-level reimbursement for outside medical services used by state hospital patients. He said at least one provider was interested in offering services at that rate and that the population involved is largely non-ambulatory long-term care patients. Members asked about availability and training, and the witness said special training could be provided. SB 1322, a broad mental health bill, drew mixed testimony. The Department of Law Enforcement supported giving crisis-intervention-trained officers more discretion to transport people to medical care instead of arresting them. The Attorney General supported the bill but recommended revisions to emergency-transport language and restoring liability protections. HHSC and Queens Hospital supported the overall goal but sought amendments to preserve the mental health emergency worker role in decision-making and to avoid negative impacts on emergency departments. The Disability Rights Center and ACLU opposed parts of the bill, arguing that it weakens due process, reduces protections in involuntary treatment and transport, and should retain a three-person treatment panel rather than reduce it to one. A Queens representative said the current program works well and reported that more than 90% of MH1 cases once went to hospitals, but that figure has dropped to about 60-70%, with about 20% now diverted to community settings or the behavioral health crisis center. No votes or final committee actions were taken in the portion provided.

Transcript Highlights:

• That data came from a state-funded program just like this, modeled after Minnesota, which led to FDA
• 09:40.720> got that led to the pivotal trial that got that led to the pivotal trial that got FDA
• 09:42.000> Onward,<00:09:42.560> which<00:09:42.720> is<00:09:42.880> a FDA
• approval for Onward, which is a FDA approval for Onward, which is a company<00:09:43.360> based
• approval for the first which led to FDA approval for the first ever<00:09:53.760> device<00:09

Keywords: 919, house, all

Summary: The meeting focused on a House counteroffer to a higher education budget and policy agreement, with Ken Savory walking members through spreadsheet changes and Mr. Hopkins reviewing policy items. On the budget side, the House adjusted several appropriations and savings targets, including state grants, child care grants, student teacher and shortage area grants, student parent support, spinal cord injury and traumatic brain injury research grants, dual training grants for legal cannabis employers, and University of Minnesota cannabis research. The House also noted no change to Minnesota State, alignment with the Senate on the summer academic enrichment program, and that remaining state grant parameters would continue to be negotiated. On policy, the House said some items were agreed to and grayed out, including campus sexual misconduct policy and treatment of appropriations. The House kept its original position on the NN Mayo Clinic Partnership and did not include K-12 direct admissions or the College Financing Literacy Act. It also proposed adjusting OHEI appropriations for competitively and legislatively named grant programs so administrative cost reserves would conform to 10% and 5% parameters when current law is below those levels. The committee then heard testimony in support of continuing the spinal cord injury/traumatic brain injury grant program at its current level. Joey Carlson described his spinal cord injury, his career path, and how the program helped advance research and industry connections, while Matthew Broadick argued the program has produced clinical trials, FDA approval-related progress, jobs, and strong return on investment. He also said the program belongs at the Office of Higher Education rather than the Department of Health because its mission better fits research and innovation. Members asked about the program’s long-term home, and the witnesses defended OHE’s role. No votes were taken; the chair thanked the House for the offer, said it would be reviewed, and recessed the meeting.